Skip to main content
Breast Cancer : Targets and Therapy logoLink to Breast Cancer : Targets and Therapy
. 2026 Mar 10;18:560682. doi: 10.2147/BCTT.S560682

SLAMF8 Promotes M2 Polarization of Macrophages and Enhances Breast Cancer Proliferation

Jilin Kong 1, Rui Tian 1, Shuyan Li 1, Hongyan Zang 1, Yan Cheng 1, Gaofeng Ni 1, Wenjing Liu 1, Liguo Gong 1,✉
PMCID: PMC12988786  PMID: 41836155

Abstract

Background

Breast cancer is characterized by a complex pathogenesis and diverse clinical manifestations. Tumor-associated macrophages (TAMs) play a pivotal role in tumorigenesis, metastasis, and response to anticancer therapies. This study aimed to analyze the functional role of signaling lymphocytic activation molecule family 8 (SLAMF8) in TAMs and its impact on breast cancer cell proliferation.

Methods

The SLAMF8 silencing in THP-1 cells was established by transfection with SLAMF8 shRNA lentiviral particles, and the THP-1 cells were induced to M0 macrophages or M2 macrophages. The M2 macrophage markers, CD11b+CD163, CD206, and IL-10, were measured by flow cytometry and Western blotting. The induced macrophages were cocultured with breast cancer cells (MCF-7 and MDA-MB-231) using a transwell insert. The viability and migration of cancer cells were measured using CCK-8 and transwell migration. The STAT6 and NF-κB pathways were measured using Western blotting. In vivo, mice were co-injected with breast cancer cells and the THP-1-derived macrophages to observe the tumor growth. The NF-κB pathway in tumor tissues was measured by immunohistochemistry and Western blotting.

Results

The SLAMF8 silencing significantly downregulated the number of THP-1-derived M2 macrophages. The viability, migration, and the STAT6 and NF-κB pathways of breast cancer cells were significantly enhanced after co-culture with M2 macrophages compared to co-culture with M0 macrophages. However, the SLAMF8 silencing markedly suppressed the promoting effects of M2 macrophage co-culture on the above factors in cancer cells. In line with the in-vitro results, co-injection with M2 macrophages significantly promoted the tumor growth. Moreover, the SLAMF8 silencing in M2 macrophages downregulated the tumor growth compared with that of cancer cells co-injected with M2 macrophages without SLAMF8 silencing.

Conclusion

This study showed that SLAMF8 silencing downregulated M2 macrophage polarization and weakened the promoting effects of M2 macrophages on breast cancer cells, suggesting a promising therapeutic strategy for breast cancer.

Keywords: tumor-associated macrophages, breast cancer, SLAMF8, THP-1 cells

Introduction

Breast cancer is one of the primary causes of malignancy-related deaths in women, characterized by intricate pathogenesis and diverse clinical manifestations, which poses challenges for unified treatment strategies.1 In clinical practice, immunohistochemical results are often used to classify the four main breast cancer subtypes. Specifically, luminal A and luminal B subtypes are hormone-receptor-positive, the HER2-enriched subtype overexpresses the human epidermal growth factor receptor 2, and triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and HER2.1,2 However, the exact mechanisms of breast cancer progression are not fully understood. Despite this lack of full understanding, the tumor microenvironment, characterized by interactions between tumor cells, stromal cells, and immune cells, further influences carcinogenesis.2 Consequently, understanding these mechanisms is vital for developing preventive strategies and targeted therapies.

Tumor microenvironment (TME) plays a pivotal role in tumorigenesis, disease progression, metastasis, and response to anticancer therapies. Tumor-associated macrophages (TAMs), as the most common type of immune cells, are present in the TME and can account for up to 50% of the solid tumor mass.3,4 As is widely known, macrophages can exhibit distinct or even opposite phenotypes, such as the pro-inflammatory classically activated M1 macrophages and the anti-inflammatory alternatively activated M2 macrophages, with the specific phenotype being determined by the extracellular microenvironment.5 M1 macrophages actively engage in phagocytosis, effectively killing pathogens and tumor cells. M1 macrophages mainly secrete pro-inflammatory cytokines, such as interleukin (IL)-1β, tumor necrosis factor (TNF), IL-12, and IL-18. These cytokines possess a strong bactericidal ability and can kill intracellular bacteria. In contrast, M2 macrophages are essential for maintaining tissue homeostasis and facilitating wound healing, yet they also promote tumorigenesis. Therefore, M2 macrophages are often classified as TAMs in the TME, and these TAMs release cytokines, chemokines, growth factors, and enzymes, such as interleukin (IL)-10, epidermal growth factor (EGF), chemokine (C-C motif) ligand 2 (CCL2), and vascular endothelial growth factor (VEGF).5,6 TAM infiltration correlates with poor prognosis in a variety of cancers, including breast cancer.5,6 The mechanisms by which TAM infiltration contributes to poor prognosis in breast cancer involve promoting tumor cell growth, angiogenesis, and immune evasion. Given the TAM contribution in breast cancer progression, TAM-focused therapeutic strategies offer substantial potential for clinical application.

The signaling lymphocytic activation molecule family (SLAMF) proteins, belonging to the CD2 family, are predominantly expressed by immune cells and associated with regulating immune responses.7 SLAMF8, also called CD353 and BLAME, is expressed by macrophages and has been reported to trigger M1 macrophage polarization during inflammation, such as non-eosinophilic chronic rhinosinusitis with nasal polyps8 and bacterial infection.9 Moreover, SLAMF8 is overexpressed in various cancers, including glioma,10 colorectal cancer,11 and prostate cancer.12 In colorectal cancer, SLAMF8 is expressed mainly on the surface of TAMs, impairs Fc receptor-mediated phagocytosis through the PI3K-Akt signaling pathway, and negatively regulates the antitumor immune response.13 Importantly, it has been reported that SLAMF8 is highly expressed in breast cancer.14 These reports suggest that SLAMF8 may be involved in the formation of TME in breast cancer. Nevertheless, the involvement of SLAMF8 in breast cancer remains unknown.

Transcription factors that promote the polarization of M2 macrophages include NF-κB p50 (p50), signal transducer and activator of transcription 6 (STAT6), peroxisome proliferator-activated receptor γ (PPAR-γ), and Krüppel-like factor 4 (KLF4).15–17 Additionally, the activation of the NF-κB pathway increases the number of M2 macrophages in the tumor immune microenvironment, thereby promoting tumor metastasis in breast cancer.18 The NF-κB subunit family mainly consists of p50, p52, RELA/p65, cREL, and RELB, and the formation of their homo- and heterodimers determines cellular homeostasis under various physiological conditions.19 In this study, we investigated the functional role of SLAMF8 in TAMs, as well as its impacts on breast cancer cell proliferation and the NF-κB p50 pathway.

Materials and Methods

Cells

Two breast cancer lines, MCF-7 (ER+) and MDA-MB-231 (triple-negative), along with THP-1 cells, were purchased from Procell (Wuhan, China). MCF-7 cells were cultured in minimum essential medium (MEM) supplemented with non-essential amino acids, 10 μg/mL insulin, 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin (P/S). MDA-MB-231 cells were cultured in DMEM containing 10% FBS and 1%P/S. THP-1 cells were cultured in RPMI-1640 containing 10% FBS, 0.05 mM β-mercaptoethanol, and 1%P/S. The culture medium for all cell lines was replaced 2–3 times weekly.

SLAMF8 Silencing in THP-1 Cells

THP-1 cells were infected with SLAMF8 shRNA#1 lentiviral particles (#sc-60273-V, Santa Cruz, China), SLAMF8 shRNA#2 lentiviral particles (#4392420, Introgen, China), or control shRNA lentiviral particles-A (#sc-108080, Santa Cruz, China) according to the instructions. The stable clones were selected using Puromycin dihydrochloride selection, and the levels of SLAMF8 mRNA were measured by reverse transcription-polymerase chain reaction (RT-qPCR).

RT-qPCR

According to the RT-PCR method,20 total RNAs from cells were extracted by Trizol and stored at −20 °C. Total mRNAs were extracted using a PureLinkTM RNA mini kit (#12183018A, Life Technologies, China), and reverse-transcribed into cDNA using a reverse transcription kit (#4388950, Life Technologies, China) according to the manufacturer’s protocols. The PCR primers for SLAMF8 were 5′-CCCAACATCAGCGAA ATAACC-3′ and 5′-GAAGAGAGTAACCAGCATCAG-3′. The results were analyzed using the 2−ΔΔCTmethod.21

Generation of M2-Like Macrophages

THP-1 cells were treated with 100 ng/mL phorbol myristate acetate (PMA) for 24 h to induce M0 macrophages. Subsequently, the PMA-treated THP-1 cells were washed with PBS and cultured in fresh medium for 24 h. Thereafter, the M0 macrophages were treated with 20 ng/mL interleukin-4 (IL-4) and IL-13 for 48 h to obtain M2 macrophages.3,22

Effects of SLAMF8 Silencing on M2 Macrophage Polarization

To analyze the effects of SLAMF8 silencing on M2 macrophage polarization, the markers of M2 macrophages, CD11b+CD163+, IL-10, and CD206, were measured. Specifically, the levels of CD11b+CD163+ were measured by flow cytometry. The levels of IL-10 and CD206 were measured by Western blotting. In addition, the expression of SLAMF8 was measured by Western blotting.

Flow Cytometry

M2 macrophages (100 μL) were cultured with 1 μL of specifically labelled antibody for 30 min at 4 °C in the dark. After dilution with PBS, the cells were analyzed within 60 min using flow cytometry (FlowJo). The antibodies included CD11b-FITC (#ab269333, Abcam, China) and CD163-PE (#ab314947, Abcam, China).

Cell Coculture

By observing the M2 polarization effect of SLAMF8 shRNA#1 and SLAMF8 shRNA#2 on macrophages, it was found that both shRNAs could significantly influence the macrophage polarization. In subsequent experiments, the SLAMF8 shRNA#1 was used for further research. According to the reported protocols,3 a transwell co-culture was performed using breast cancer cells and THP-1-derived macrophages. The THP-1-derived macrophages included the control shRNA-infected M0, SLAMF8 shRNA#1-infected M0, control shRNA-infected M2, and SLAMF8 shRNA#1-infected M2 macrophages. Briefly, the breast cancer cells (5×104 cells/well) were pre-seeded into a transwell-compatible 6-well plate, and the macrophages (4×105 cells) were seeded into a 0.4 μm pore size transwell insert. After placing the transwell inserts into the wells, the co-culture was incubated for 72 h at 37°C, 5% CO2.

Cancer Cell Viability

Cancer cells (2×103/well) were seeded into a 96-well plate. Then, 10 μL of CCK-8 solution (#C0039, Beyotime, China) was added to each well. The plate was incubated at 37°C, 5% CO2 for 4 h. Subsequently, the optical density of each well was measured at 450 nm.

Cancer Cell Migration

Cancer cells (2×104) were cultured in Transwell inserts for 24 h, then the inserts containing cells were transferred to a new plate with ice-cold methanol and incubated for 10 min. After aspirating the methanol, the inserts were incubated in Formal-FixxTM 1x solution for 10 min. Subsequently, they were stained with 0.5% crystal violet solution (#C0121, Beyotime, China) for 10 min. After aspirating the crystal violet solution, the inserts were rinsed with MilliQ water. Next, the inner parts of the inserts were cleaned using cotton swabs. The inserts were left to dry overnight and then photographed. Finally, the results were quantified using ImageJ software.

Western Blotting

Total proteins in cells were extracted using a RIPA lysis buffer (#P0013B, Beyotime, China), and their concentration was determined by the BCA method. Protein samples were separated by 12% gel electrophoresis and then transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% milk and incubated with primary antibodies overnight at 4°C. After washing with TBS containing 0.1% Tween-20 (TBST), the membranes were incubated with the secondary antibody for 90 min. Following another wash with TBST, the chemiluminescence signal was detected using an enhanced chemiluminescence kit (#P0018M, Beyotime, China). The semi-quantification was analyzed using ImageJ software. The antibodies were shown in Table 1.

Table 1.

Antibodies in This Study

Antibody Host Code Dilution Source
SLAMF8 Rabbit PA5-116184 WB: 1:1000 Invitrogen
IL-10 Rabbit 14-7108-81 WB: 1:1000 Invitrogen
CD206 Rabbit PA5-101657 WB: 1:600
IHC: 1:50
Invitrogen
PPAR-γ Rabbit MA5-32533 WB: 1:1000 Invitrogen
Phospho-STAT6 (Tyr641) Rabbit PA5-104892 WB: 1:600 Invitrogen
STAT6 Rabbit RAB01890 WB: 1:600 Invitrogen
Phospho-NF-κB p50 (S337) Rabbit Ab28849 WB: 1:300
IHC: 1:50
Abcam
NF-κB p50 Rabbit Ab209795 WB: 1:1000 Abcam
β-actin Rabbit MA5-32479 WB: 1:20,000 Invitrogen
Goat anti-Rabbit IgG (H+L) Goat 31460 WB: 1:20,000
IHC: 1:800
Invitrogen
Ki-67 Rabbit MA5-14520 IHC: 1:100 Invitrogen

Abbreviations: WB, Western blotting; IHC, Immunohistochemistry.

Animals

Forty-eight female nude mice, 4–6 weeks and 12–18 g, were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd (Shandong, Jinan, China). All animals were housed in specific-pathogen-free environments, with unrestricted access to food and water.

Animal Groups

Group assignment was accomplished using a computer-based random number generator. In the tumorigenicity assay induced by MCF-7 cells, 24 mice were randomly divided into four groups (six mice in each group): the group injected with MCF-7 cells alone, the group co-injected with MCF-7 cells and M0 macrophages, the group co-injected with MCF-7 cells and M2 macrophages, and the group co-injected with MCF-7 cells and M2 macrophages infected with SLAMF8 shRNA#1. A suspension containing 5×105 MCF-7 cells and 5×105 macrophages in 200 μL was subcutaneously injected into the flank of each mouse.23

In the tumorigenicity assay induced by MDA-MB-231 cells, the same animal groups (six mice in each group) as those in the above-mentioned MCF-7 cell-induced tumorigenicity assay were adopted (ie, the group injected with MDA-MB-231 cells alone, the group co-injected with MDA-MB-231 cells and M0 macrophages, etc).

Tumor Observation and Sample Collection

Five days after injection, the tumor sizes Inline graphic were measured every 5 days. Twenty days after injection, the mice were sacrificed by terminal anesthesia using 100 mg/kg pentobarbital sodium injection. The tumor weights were measured and fixed in 4% paraformaldehyde.

Immunohistochemistry

The fixed tissues were embedded in paraffin and sliced into sections with a thickness of 4 μm. The sections were treated with xylene twice, followed by treatment with gradient ethanol (100%, 90%, 80%, 75%). Then, they were treated with 3% hydrogen peroxide for 5 min and incubated in a pressure cooker for 30 min in 0.01 M citrate buffer. After being washed twice with PBS, the sections were incubated with primary antibodies (as listed in Table 1) overnight at 4 °C. Subsequently, the sections were incubated with the secondary antibody for 90 min and counterstained with hematoxylin. Finally, the sections were treated with gradient ethanol (80%, 90%, 95%, 100%), then with xylene twice, and sealed with neutral gum. The results were quantitatively analyzed using ImageJ software.

Statistical Analysis

Statistical analysis was performed using SPSS (version 20.0, IBM, Chicago, IL, USA). The Shapiro–Wilk test was used to examine the normal distribution of the data. One-way analysis of variance, followed by the post-hoc Tukey’s test, was applied to assess the significance of differences among multiple groups. A P-value less than 0.05 was considered statistically significant.

Results

SLAMF8 Silencing in THP-1 Cells

First, stable SLAMF8 silencing in THP-1 cells was achieved by infecting the cells with SLAMF8 shRNA lentiviral particles. Then, the transfected THP-1 cells were induced to M2 macrophages to analyze the effects of SLAMF8 silencing on the M2 macrophage polarization (Figure 1A). The results of RT-qPCR (Figure 1B) and Western blotting (Figure 1C) confirmed that SLAMF8 mRNA levels in THP-1 cells were significantly downregulated after infection with SLAMF8 shRNA#1 or shRNA#2, compared with the control shRNA infection (P < 0.01). Additionally, there was no significant difference in the levels of SLAMF8 mRNA between the control shRNA-infected cells and the untreated control cells.

Figure 1.

Figure 1

SLAMF8 silencing was achieved in THP-1 cells. (A) Flowchart of THP-1 cell treatment. (B) The levels of SLAMF8 mRNA were measured by RT-qPCR. (C) The levels of SLAMF8 protein were measured by Western blotting. n=3. **P < 0.01.

SLAMF8 Silencing Downregulated M2 Macrophage Polarization

To observe the M2 macrophage polarization, the numbers of M2 macrophages were determined by measuring the expression of CD11b+CD163 (Figure 2A). The results showed that the SLAMF8 shRNA#1 or shRNA#2 transfection significantly downregulated the numbers of M2 macrophages compared with the control shRNA transfection (P < 0.01). Moreover, the M2 macrophage makers, CD206 and IL-10, were measured by Western blotting (Figure 2B and C). The results showed that transfection with either SLAMF8 shRNA#1 or shRNA#2 significantly reduced the levels of CD206 and IL-10 compared with the control shRNA transfection in M2 macrophages (P < 0.05). However, in M0 macrophages, transfection with SLAMF8 shRNA#1 or shRNA#2 did not significantly impact the mentioned above factors.

Figure 2.

Figure 2

Effects of SLAMF8 silencing on M2 polarization of macrophages. (A) The expression of CD11b+CD163 was measured by flow cytometry. (B and C) The levels of CD206 and IL-10 proteins were measured by Western blotting. n=3. *P < 0.05, **P < 0.01.

SLAMF8 Silencing in M2 Macrophages Regulated the Cancer Proliferation and Migration

To analyze the effects of SLAMF8 silencing in macrophages on co-cultured breast cancer cells, a transwell co-culture was performed using breast cancer cells (MCF-7 and MDA-MB-231 cell lines) and THP-1-derived macrophages (Figure 3A). The results demonstrated that the M2 macrophage co-culture significantly enhanced the cancer cell viability (Figure 3B) and migration (Figure 3C) compared with the M0 macrophage co-culture (P < 0.01). However, the SLAMF8 silencing in M2 macrophages markedly suppressed the effects of M2 macrophage co-culture on breast cancer cells (P < 0.01). Meanwhile, the SLAMF8 silencing in M0 macrophage did not significantly impact the cancer cell viability (Figure 3B) and migration (Figure 3C).

Figure 3.

Figure 3

Effects of SLAMF8 silencing in macrophages on the viability and migration of breast cancer cells. (A) Flowchart of cell co-culture. (B) The cell viabilities were measured by CCK-8. (C) The cell migration was measured by transwell migration. n=3. **P < 0.01.

SLAMF8 Silencing in M2 Macrophages Regulated the STAT6 and NF-κB p50 Pathways in Co-Cultured Cancer Cells

Given the observed effects of SLAMF8 silencing in M2 macrophages on the behavior of co-cultured breast cancer cells, we further investigated its impact on the intracellular STAT6 and NF-κB p50 pathways. First, the levels of PPAR-γ and p-STAT6 (y641)/STAT6 proteins in the MCF-7 (Figure 4A) and MDA-MB-231 (Figure 4B) cells were measured, and the results showed that co-culturing with M2 macrophages significantly upregulated these protein levels compared to co-culturing with M0 macrophages (P < 0.01). Subsequently, the levels of p-NF-κB p50(S337)/NF-κB p50 protein in the MCF-7 (Figure 4C) and MDA-MB-231 (Figure 4D) cells were measured, and it was found that these levels were significantly upregulated following co-culture with M2 macrophages as opposed to M0 macrophages (P < 0.01). Moreover, SLAMF8 silencing in M2 macrophages attenuated the impacts of M2 macrophages on the mentioned above factors (P < 0.05). However, the SLAMF8 silencing in M0 macrophages did not significantly impact the STAT6 and NF-κB p50 pathways in cancer cells.

Figure 4.

Figure 4

Effects of SLAMF8 silencing in macrophages on the STAT6 and NF-κB p50 pathways of breast cancer cells. The levels of PPAR-γ and p-STAT6 (y641)/STAT6 proteins in MCF-7 (A) and MDA-MB-231 (B) cells were measured by Western blotting. The levels of p-NF-κB p50 (S337)/NF-κB p50 proteins in MCF-7 (C) and MDA-MB-231 (D) were measured by Western blotting. n=3. *P < 0.05, **P < 0.01.

SLAMF8 Silencing in M2 Macrophages Affected the Tumor Growth

To further confirm the in-vitro findings, breast cancer cells co-injected with macrophages were subcutaneously injected into female nude mice. The animal groups are shown in Figure 5A. The tumor size (Figure 5B), tumor weights (Figure 5C), and Ki-67 expressions in tumor tissues (Figure 5D) were measured, and no significant difference was found between the group injected with cancer cells alone and the group in which cancer cells were co-injected with M0 macrophages. However, in the group where cancer cells were co-injected with M2 macrophages, the aforementioned factors were significantly increased compared with the group injected with cancer cells alone (P < 0.01). Meanwhile, SLAMF8 silencing in M2 macrophages attenuated the impacts of co-injection with M2 macrophages on the mentioned above factors (P < 0.05).

Figure 5.

Figure 5

Effects of SLAMF8 silencing in M2 macrophages on the tumor growth. (A) Flowchart of animal treatment. (B) The tumor volumes were measured every five days. (C) The tumor weights were measured. (D) The Ki-67 expressions in tumor tissues were measured by immunohistochemistry. n=6. *P < 0.05, **P < 0.01.

SLAMF8 Silencing in M2 Macrophages Regulated the NF-κB p50 Pathway in Tumor Tissues

The levels of p-NF-κB p50 (S337) in the tumor tissues were measured by immunohistochemistry (Figure 6A). Consistent with the in-vitro findings, the levels of p-NF-κB p50 (S337) were significantly upregulated in the group where cancer cells were co-injected with M2 macrophages compared with the group injected with cancer cells alone (P<0.01, Figure 6B). SLAMF8 silencing in M2 macrophages significantly reduced the effects of co-injection with M2 macrophages on the levels of p-NF-κB p50 (S337) (P < 0.05, Figure 6B). Concurrently, the levels of p-NF-κB p50 (S337)/NF-κB p50 protein were measured by Western blotting (Figure 6C). The results also showed that their levels were significantly increased in the group where cancer cells were co-injected with M2 macrophages (P<0.01), and that SLAMF8 silencing in M2 macrophages attenuated the effects of co-injection with M2 macrophages (P < 0.05).

Figure 6.

Figure 6

Effects of SLAMF8 silencing in M2 macrophages on the NF-κB p50 pathway in tumor tissues. (A) The expressions of p-NF-κB p50(S337) in the tumors were measured by immunohistochemistry. (B) The results of p-NF-κB p50(S337) expression were analyzed using ImageJ software. (C) The levels of p-NF-κB p50(S337)/NF-κB p50 proteins were measured by Western blotting. n=6. *P < 0.05, **P < 0.01.

To ensure the M2 macrophage population in vivo, the M2 macrophage marker, CD206, was measured in tumor tissues. In the MCF-7-induced (Figure 7A) and MDA-MB-231-induced (Figure 7B) tumor tissues, no significant difference was found between the group injected with cancer cells alone and the group in which cancer cells were co-injected with M0 macrophages. However, the levels of CD206 were significantly increased in the group where cancer cells were co-injected with M2 macrophages compared with the group injected with cancer cells alone (P<0.01), and SLAMF8 silencing in M2 macrophages decreased the CD206 expression in tumor tissues (P < 0.05).

Figure 7.

Figure 7

Co-injection with M2 macrophages enhanced the CD206 expression in tumor tissues. The expressions of CD206 in MCF-7-induced tumor tissues (A) and MDA-MB-231-induced tumor tissues (B) were measured by immunohistochemistry. n=6. *P < 0.05, **P < 0.01.

Discussion

In breast cancer, it has been reported that TAM infiltration and metastasis are linked to poor clinical outcomes.24 Generally, TAMs possess the M2 phenotype, which is characterized by proangiogenic properties. In line with previous reports,5,6 our results showed that co-culturing with M2 macrophages enhanced the breast cancer cell proliferation and migration, whereas co-culturing with M0 macrophages had no significant impact on the behaviors of breast cancer cells.

SLAMF8 is predominantly expressed on the surface of immune cells.25 Its high expression is associated with an enhanced T-cell-mediated immune phenotype and activated IFN-γ signaling pathway in glioma10 and gastrointestinal cancer.26 Additionally, intervention of SLAMF8 during bacterial infection downregulates the activation of mouse M1 macrophages via the PI3K pathway.9 In chronic rhinosinusitis with nasal polyps, the upregulation of SLAMF8 promotes M1 macrophage polarization, drives epithelial-mesenchymal transition (EMT), disrupts epithelial tight junctions, and exacerbates disease severity.8 These studies demonstrate that the SLAMF8 expressed by macrophages may play a crucial role in the polarization of TAMs, potentially affecting tumor development and the response to treatment. Our study confirmed that the IL-4 and IL-13-induced M2 polarization was downregulated by SLAMF8 silencing. Furthermore, the SLAMF8 silencing attenuated the effects of M2 macrophages on the proliferation and migration of breast cancer cells. These results demonstrate that SLAMF8 modulates the interactions between M2 macrophages and breast cancer cells.

The polarization of M2 macrophages is influenced by various factors, such as NF-κB p50, STAT6, and PPAR-γ.15–17 The major subunit p65 forms a dimeric complex with p50 and activates the NF-κB pathway, and this activation induces the expression of genes related to cell survival, cell death, and inflammation in breast cancer.18,27 In glioblastoma, the deficiency of host NF-κB p50 in mice can increase the survival rate and reduce the M2 polarization induced by T cells.15 Blocking phosphorylation of STAT6 (Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer.28 PPAR-γ, a regulator of M2 macrophages, promotes M2 polarization by integrin β3 in breast cancer.29 STAT6 also functions as a facilitating factor for PPAR-γ by promoting DNA-binding.29 These reports support our findings that co-culture with M2 macrophages enhanced the expression of PPAR-γ, the phosphorylation of STAT6 (Tyr641), and the phosphorylation of NF-κB p50 (S337) in breast cancer cells. Meanwhile, SLAMF8 silencing in M2 macrophages downregulated the expression of PPAR-γ, the phosphorylation of STAT6 (Tyr641), and the phosphorylation of NF-κB p50 (S337) in breast cancer cells. Moreover, the in-vitro findings were confirmed by the in-vivo experiments, that co-injection with M2 macrophages enhanced tumor growth, and SLAMF8 silencing in M2 macrophages attenuated the effects of M2 macrophages on tumor growth.

However, exploring the effects of SLAMF8 on other immune cells within the TME is needed. For example, its impact on macrophage subsets following interference, as well as its role in other endogenous immune populations, such as T cells and myeloid-derived suppressor cells, remains to be explored. Additionally, primary human macrophages or patient-derived co-cultures should be used for further verification and research, which is essential for ensuring the translational relevance of the study.

Conclusions

This study demonstrated that SLAMF8 silencing downregulated M2 macrophage polarization and weakened the promoting effects of M2 macrophages on breast cancer cells. Based on this finding, SLAMF8 silencing in TAMs is a promising therapeutic strategy for breast cancer.

Funding Statement

This study was funded by Yantai Science and Technology Innovation Development (No. 2023YD020).

Abbreviations

SLAMF8, signaling lymphocytic activation molecule family 8; TAMs, tumor-associated macrophages; TNBC, triple-negative breast cancer; ER, estrogen receptor; PR, progesterone receptor; TME, tumor microenvironment; IL, interleukin; EGF, epidermal growth factor; CCL2, chemokine (C-C motif) ligand 2; VEGF, vascular endothelial growth factor; MEM, minimum essential medium; FBS, fetal bovine serum; P/S, penicillin-streptomycin; RT-qPCR, reverse transcription-polymerase chain reaction; TBST, TBS containing 0.1% Tween-20; WB, Western blotting; IHC, immunohistochemistry.

Data Sharing Statement

The datasets that were produced throughout the present study can be obtained from the corresponding author.

Ethics Approval

All animal studies were approved by the Ethics Committee of Yantaishan Hospital (Approval No. 2023-412) and were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health) and ARRIVE 2.0 Guidelines “Animal Research: Reporting of In Vivo Experiments”.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49. doi: 10.1038/s41392-024-02108-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024;25(14):7517. doi: 10.3390/ijms25147517 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mazan A, Marusiak AA. Protocols for co-culture phenotypic assays with breast cancer cells and THP-1-derived macrophages. J Mammary Gland Biol Neoplasia. 2024;29(1):4. doi: 10.1007/s10911-024-09556-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Han C, Deng Y, Xu W, et al. The roles of tumor-associated macrophages in prostate cancer. J Oncol. 2022;2022:8580043. doi: 10.1155/2022/8580043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Melwani PK, Checker R, Balla MMS, Pandey BN. Crosstalk between macrophages and breast cancer cells: networking within tumors. Results Probl Cell Differ. 2024;74:213–14. doi: 10.1007/978-3-031-65944-7_8 [DOI] [PubMed] [Google Scholar]
  • 6.Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL. Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol. 2021;12:643771. doi: 10.3389/fimmu.2021.643771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lin Z, Sun G, Ou Z, Wei Y, Wang Y. SLAMF8 promotes atherosclerosis by activating the TLR4 signaling pathway in rheumatoid arthritis. Altern Ther Health Med. 2024. [PubMed] [Google Scholar]
  • 8.Li D, Yu L, Zi J, et al. Signaling lymphocytic activation molecule family 8 disrupts epithelial barrier in chronic rhinosinusitis with nasal polyps through M1 macrophage polarization. Ann Allergy Asthma Immunol. 2025;134(4):431–441.e4. doi: 10.1016/j.anai.2025.01.020 [DOI] [PubMed] [Google Scholar]
  • 9.Romero-Pinedo S, Barros DIR, Ruiz-Magaña MJ, et al. SLAMF8 downregulates mouse macrophage microbicidal mechanisms via PI3K pathways. Front Immunol. 2022;13:910112. doi: 10.3389/fimmu.2022.910112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zou CY, Guan GF, Zhu C, et al. Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma. CNS Neurosci Ther. 2019;25(3):333–342. doi: 10.1111/cns.13041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zhang Y, Zhang Q, Han X, et al. SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer. Transl Oncol. 2023;31:101654. doi: 10.1016/j.tranon.2023.101654 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Su Q, Zhu Y, He B, Dai B, Mu W, Tian J. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer. Eur J Med Res. 2023;28(1):545. doi: 10.1186/s40001-023-01522-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Liu Z, Hu J, Han X, et al. SLAMF8 regulates Fc receptor-mediated phagocytosis in mouse macrophage cells through PI3K-Akt signaling. Immunol Lett. 2025;273:106990. doi: 10.1016/j.imlet.2025.106990 [DOI] [PubMed] [Google Scholar]
  • 14.López-Cade I, García-Barberán V, Cabañas Morafraile E, et al. Genomic mapping of copy number variations influencing immune response in breast cancer. Front Oncol. 2022;12:975437. doi: 10.3389/fonc.2022.975437 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Barberi T, Martin A, Suresh R, et al. Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother. 2018;67(10):1491–1503. doi: 10.1007/s00262-018-2184-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.He Y, Gao Y, Zhang Q, Zhou G, Cao F, Yao S. IL-4 switches microglia/macrophage M1/M2 polarization and alleviates neurological damage by modulating the JAK1/STAT6 pathway following ICH. Neuroscience. 2020;437:161–171. doi: 10.1016/j.neuroscience.2020.03.008 [DOI] [PubMed] [Google Scholar]
  • 17.Fang C, Zhong R, Lu S, et al. TREM2 promotes macrophage polarization from M1 to M2 and suppresses osteoarthritis through the NF-κB/CXCL3 axis. Int J Bio Sci. 2024;20(6):1992–2007. doi: 10.7150/ijbs.91519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zhang M, Liu ZZ, Aoshima K, et al. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Sci Transl Med. 2022;14(630):eabf5473. doi: 10.1126/scitranslmed.abf5473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lalle G, Twardowski J, Grinberg-Bleyer Y. NF-κB in cancer immunity: friend or foe? Cells. 2021;10(2):355. doi: 10.3390/cells10020355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bachman J. Reverse-transcription PCR (RT-PCR). Methods Enzymol. 2013;530:67–74. doi: 10.1016/b978-0-12-420037-1.00002-6 [DOI] [PubMed] [Google Scholar]
  • 21.Damgaard MV, Treebak JT. Protocol for qPCR analysis that corrects for cDNA amplification efficiency. STAR Protocols. 2022;3(3):101515. doi: 10.1016/j.xpro.2022.101515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen J, Tang Y, Qin D, et al. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway. J Transl Med. 2023;21(1):923. doi: 10.1186/s12967-023-04804-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wei C, Yang C, Wang S, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18(1):64. doi: 10.1186/s12943-019-0976-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Stavrou M, Constantinidou A. Tumor associated macrophages in breast cancer progression: implications and clinical relevance. Front Immunol. 2024;15:1441820. doi: 10.3389/fimmu.2024.1441820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Husseni A, Altalbawy FMA, Kaur I, et al. SLAMF8 (BLAME) as a novel immune checkpoint: implications for inflammation, autoimmunity, and oncology. Pathol Res Pract. 2025;272:156072. doi: 10.1016/j.prp.2025.156072 [DOI] [PubMed] [Google Scholar]
  • 26.Zhang Q, Cheng L, Qin Y, et al. SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers. Clin Transl Immunol. 2021;10(10):e1347. doi: 10.1002/cti2.1347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shinde A, Chandak N, Singh J, et al. TNF-α induced NF-κB mediated LYRM7 expression modulates the tumor growth and metastatic ability in breast cancer. Free Radic Biol Med. 2024;211:158–170. doi: 10.1016/j.freeradbiomed.2023.12.018 [DOI] [PubMed] [Google Scholar]
  • 28.Rahal OM, Wolfe AR, Mandal PK, et al. Blocking Interleukin (IL)4- and IL13-mediated phosphorylation of STAT6 (Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2018;100(4):1034–1043. doi: 10.1016/j.ijrobp.2017.11.043 [DOI] [PubMed] [Google Scholar]
  • 29.Shu Y, Qin M, Song Y, et al. M2 polarization of tumor-associated macrophages is dependent on integrin β3 via peroxisome proliferator-activated receptor-γ up-regulation in breast cancer. Immunology. 2020;160(4):345–356. doi: 10.1111/imm.13196 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets that were produced throughout the present study can be obtained from the corresponding author.


Articles from Breast Cancer : Targets and Therapy are provided here courtesy of Dove Press

RESOURCES